Valproic acid hepatic fatalities. III. U.S. experience since 1986.
about
Off-label psychopharmacologic prescribing for children: history supports close clinical monitoringMolecular and therapeutic potential and toxicity of valproic acidModifications of antiepileptic drugs for improved tolerability and efficacySpecial considerations in the treatment of patients with bipolar disorder and medical co-morbiditiesScience review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adultsValproic acid-associated low fibrinogen and delayed intracranial hemorrhage: case report and mini literature review.The current evaluation and treatment of infantile spasms among members of the Child Neurology Society.Human milk biomonitoring data: interpretation and risk assessment issues.Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholismValproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts.Use of new antiepileptic drugs in the treatment of childhood epilepsy.Felbamate.Adverse effects of antiepileptic drugs.Anticonvulsants and breast feeding: a critical review.Idiosyncratic reactions: new methods of identifying high-risk patients.Treatment of epilepsy in the multiply handicapped.Mechanisms of drug-induced liver injury: from bedside to bench.A review of bipolar disorder in adults.Retrospective evaluation of the effect of valproate therapy on transaminase elevations in patients with hepatitis C.Mechanisms of liver injury relevant to pediatric hepatology.Infantile spasms and Lennox-Gastaut syndrome.Identifying genomic and developmental causes of adverse drug reactions in children.Children versus adults: pharmacokinetic and adverse-effect differences.Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States.The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments.Developmental and pediatric pharmacogenomics.Risk factors for idiosyncratic drug-induced liver injury.Antiepileptic drug development for "therapeutic orphans".Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.Divalproex sodium in the treatment of pediatric psychiatric disorders.Management options for bipolar disorder in children and adolescents.Valproate as a mainstay of therapy for pediatric epilepsy.Research in child and adolescent psychopharmacology: recent accomplishments and new challenges.Role of valproate across the ages. Treatment of epilepsy in children.Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity.Minimising the potential for metabolic activation in drug discovery.Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity.Antiepileptic drug treatment in children.Idiosyncratic adverse reactions to antiepileptic drugs.
P2860
Q21202071-469A0CDE-5534-4C0A-920C-99B4489199A4Q21296867-9885455E-2361-4152-8B1F-80B996304717Q24651951-346C86DC-65D4-4B7B-9A81-378A5AF407A4Q24806762-9318BBAD-AA7B-42EC-9AD7-493FD0093B4DQ24813193-30A4713B-4587-4051-9047-6E974EFE10BCQ28369097-15E76AC8-7923-4533-85C4-95A13B0F6A4AQ30450388-FA428855-3B95-43EC-B265-F16FBE293CD4Q30455995-84D66C37-62E5-4ADB-B514-0E7CADBAD842Q31006357-3FA838C5-CDEE-41A9-ADB9-BAAD0C0401E6Q33548809-0C56484E-B89A-4AA1-98A8-F58182D3E9E3Q33581698-9D0D2309-85C5-480B-83E2-1EF6D5747B17Q33756721-9C700DC1-A072-4ED5-9642-6679F8AEE5CFQ33756783-B57C696C-0565-4C95-A1B2-AD82BE24A8A3Q33961524-E8990FF0-1FE5-4800-A45F-ACAF4D289FCAQ33999176-C5737C5A-110F-4FEE-839F-ACD3054D3AFBQ34090578-6E3ED445-7211-4BB9-A6B8-7A3EF78B6A36Q34099234-64676748-297E-4577-890A-0AD80D477B40Q34169362-4860DB82-431F-43A4-B062-6A31D6484C20Q34237178-DE4C000B-9519-48C8-8951-EA96A5AE805AQ34443321-A8CC26D4-722A-495D-9D0F-B89CBAA9283AQ34559789-8D6B63E5-8DB1-493B-A96A-48504560083AQ34599704-68EC19CB-76D5-49C5-B0A8-BC891B1445F7Q34603032-E90ABD4C-C97E-484E-B37E-00E526CBDEDAQ34680689-9237FCFA-08E8-44B0-B6F7-3ECA490C920FQ34785900-0B90FB78-F8DE-4F77-B497-4B82692DAC21Q34998063-AA117CDF-4C03-4742-84A1-A043012CCD07Q35116112-726DEA66-6E70-4CF6-B9B9-DD0113633A2BQ35168108-6DEB98E6-8457-4FED-82BB-9E163BB34F73Q35200123-4A8780A9-E12D-4467-A13A-797A4101ABDEQ35624622-91261A7C-C97B-4217-BF48-A67B184CAC41Q36106793-0E827F5C-D393-41DC-9013-20D0B01123C1Q36284465-0BEC6CE3-F363-48E2-9367-DB68C8D31741Q36445471-633E4945-1953-4383-9BA9-BFF9FA156365Q36485658-87486801-ED7D-4929-9940-EE75BB637614Q36507532-33A4E182-406C-4CD7-A17D-3FDF85128C4BQ36548488-6AAC8894-4125-47EF-8FE8-575C9D604A94Q36572637-42F217A9-FF18-49AE-8740-9C9390429426Q36673575-F06C15DF-EE74-43E1-A3D9-5A0291E0E886Q36730668-0F8BDAFB-DA78-4A15-8BD4-4DFC14EC1E15Q36770454-5DC663BE-E9CA-4536-B47C-9FAFC52F97D3
P2860
Valproic acid hepatic fatalities. III. U.S. experience since 1986.
description
1996 nî lūn-bûn
@nan
1996 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Valproic acid hepatic fatalities. III. U.S. experience since 1986.
@ast
Valproic acid hepatic fatalities. III. U.S. experience since 1986.
@en
type
label
Valproic acid hepatic fatalities. III. U.S. experience since 1986.
@ast
Valproic acid hepatic fatalities. III. U.S. experience since 1986.
@en
prefLabel
Valproic acid hepatic fatalities. III. U.S. experience since 1986.
@ast
Valproic acid hepatic fatalities. III. U.S. experience since 1986.
@en
P356
P1433
P1476
Valproic acid hepatic fatalities. III. U.S. experience since 1986.
@en
P2093
A E Bryant
F E Dreifuss
P304
P356
10.1212/WNL.46.2.465
P407
P577
1996-02-01T00:00:00Z